Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.
Baker, Bartrum W
McGown, Alan T
Norton, John D
Fox, Brian W
AffiliationCRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractApproximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.
CitationImmunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. 1994, 69 (3):609-12 Br. J. Cancer
JournalBritish Journal of Cancer
- p53 mutations and overexpression in locally advanced breast cancers.
- Authors: Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F
- Issue date: 1994 Jun
- p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
- Authors: Laframboise S, Chapman W, McLaughlin J, Andrulis IL
- Issue date: 2000 Sep-Oct
- Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
- Authors: Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T
- Issue date: 1994 Dec
- p53 mutations and expression in ovarian cancers: correlation with overall survival.
- Authors: Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, el-Naggar A, Press MF
- Issue date: 1999 Jan
- Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
- Authors: Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A
- Issue date: 1993 May